Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of biomarkers associated with res...

Full description

Bibliographic Details
Main Authors: Shayista Akbar, Afsheen Raza, Reyad Mohsin, Aladdin Kanbour, Shahnaz Qadri, Aijaz Parray, Abdul Rehman Zar Gul, Anite Philip, Suma Vijayakumar, Maysaloun Merhi, Shereena Hydrose, Varghese Philipose Inchakalody, Rajaa Al-Abdulla, Wafa Abualainin, Shaza Abu Sirriya, Issam Al-Bozom, Shahab Uddin, Omar Muhammad Khan, Mohamed Izham Mohamed Ibrahim, Ussama Al Homsi, Said Dermime
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
exosomes
NSCLC
biomarkers
immune-checkpoint inhibitors
immune-oncological-checkpoints
cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1097117/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1097117/full

Similar Items